On 23 March 2010, orphan designation (EU/3/10/726) was granted by the European Commission to Protalix B.V., the Netherlands, for taliglucerase alfa for the treatment of Gaucher disease.
The sponsorship was transferred to Pfizer Limited, United Kingdom, in September 2010.
- What is Gaucher disease?
Gaucher disease is an inherited disorder that is caused by the lack of an enzyme called glucocerebrosidase. This enzyme normally breaks down a fatty waste product called glucocerebroside. Without the enzyme, glucocerebroside builds up in the body, typically in the liver, spleen and bone marrow. This causes a wide range of symptoms, including anaemia (low red blood cell counts), tiredness, easy bruising and a tendency to bleed, an enlarged spleen and liver, and bone pain and fractures.
Gaucher disease is a long-term, debilitating and life-threatening disease that is associated with a reduced life expectancy if left untreated.
- What is the estimated number of patients affected by the condition?
At the time of designation, Gaucher disease affected approximately 0.3 in 10,000 people in the European Union (EU)*. This is equivalent to a total of around 15,000 people, and is below the threshold for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and knowledge of the Committee for Orphan Medicinal Products (COMP).
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 27), Norway, Iceland and Liechtenstein. This represents a population of 506,500,000 (Eurostat 2010).
- What treatments are available?
At the time of designation, two medicines, imiglucerase and miglustat, were authorised for the treatment of Gaucher disease in the EU. Imiglucerase is an ‘enzyme replacement therapy’ that works by replacing the missing enzyme. Miglustat, which blocks the production of glucocerebrosides, can only be used in patients who cannot receive enzyme replacement therapy.
The sponsor has provided sufficient information to show that taliglucerase alfa might be of significant benefit for patients with Gaucher disease because it may represent an alternative treatment to imiglucerase, should the long-term supply problems that have occurred with this medicine happen again in the future. Taliglucerase alfa may also improve the treatment of patients with the condition, particularly with respect to bone problems. These assumptions will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.
- How is this medicine expected to work?
Taliglucerase alfa is an enzyme replacement therapy that is expected to work by replacing the missing enzyme in Gaucher disease, helping to break down glucocerebroside and stopping it building up in the body. Taliglucerase alfa is produced by a method known as ‘recombinant DNA technology’: it is made by plant cells that have received a gene (DNA), which make them able to produce the enzyme.
- What is the stage of development of this medicine?
The effects of taliglucerase alfa have been evaluated in experimental models.
At the time of submission of the application for orphan designation, clinical trials with taliglucerase alfa were ongoing in patients with Gaucher disease.
At the time of submission, taliglucerase alfa was not authorised anywhere in the EU for Gaucher disease. Orphan designation of taliglucerase alfa had been granted in the United States of America for Gaucher disease.
In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 6 January 2010 recommending the granting of this designation.
- Opinions on orphan medicinal product designations are based on the following three criteria
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
|Name||Language||First published||Last updated|
|EU/3/10/726: Public summary of opinion on orphan designation: Taliglucerase alfa for the treatment of Gaucher disease||(English only)||26/03/2010||10/03/2011|
|Active substance||Taliglucerase alfa|
|Disease/condition||treatment of Gaucher disease|
|Date of decision||23/03/2010|
|Orphan decision number||EU/3/10/726|
Review of designation
Sponsor’s contact details
Telephone: +44 13 04 61 61 61
Telefax: +44 13 04 65 62 21
Patient associations’ contact points
For contact details of patients’ organisations whose activities are targeted at rare diseases see:
- Orphanet, a database containing information on rare diseases which includes a directory of patients’ organisations registered in Europe.
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.